Advanced drug delivery 1 Flashcards
What is the aim of drug delivery and targeting?
To deliver a certain drug to its precise site of action, avoiding all other tissues in the body, at the right concentration for the right time
Drug release and drug plasma levels - Conventional dosage forms
Depend essentially on physicochemical properties of the API
Drug release and drug plasma levels -
Non-conventional dosage forms
Determined by the technological characteristics of the formulation - e.g. MR, if drug release from formulation slow then drug delivery is also slow
Drug release can be modified in terms of:
RATE: e.g. fast release, sustained release - depending on therapeutic application
TIME: e.g. how long after administration does drug release begin.
SPACE: drug release happens in specific areas - targeted
Paul Ehrlich: Magic bullet approach
Concept of finding a selective target
Refers to an API that is POTENT and SELECTIVE i.e. kills the target in the human host without harming the host itself
1st order targeting
Targeting an organ or tissue e.g. liver targeting
2nd order targeting
targeting a certain type of cells e.g. tumour cells
3rd order targeting
targeting an intracellular component e.g. lysosomes
A pharmaceutical company has developed a novel technology that allows drug release only in the endosomes of kidney cells. Which type of targeting is this?
3rd order because it is targeting an intracellular component
What are the three different approaches in drug targeting
Magic bullet: API is potent and selective
Prodrug: pharmacologically inactive derivative of the drug which is activated at site of action
Macromolecular carrier: carrier transports drug to site of action
Magic bullet - Monoclonal antibodies
Antibodies = proteins produced in response to exposure to antigen
- Monoclonal antibodies (Mabs)
- Polycloncal antibodies
Considered as magic bullets because of their inherent capacity for specificity
Monoclonal antibodies
Responsible for a single antigen
Polyclonal
Responsible for more than one antigen
Describe the structure of antibody
Two heavy chains (H)
Two light chains (L)
The chains are connected by disulphide bridges
Dotted areas at the tips are the antigen binding site (ABS)
Arms are the Fragment antigen binding (FAB) which contain the ABS
3 examples of Mabs on the market
- OKT3
First mab to reach market
Anti-CD3 antibody
Prevents rejection of kidney transplant - Abciximab
Prevents cardiac ischemic complications - Trastuzumab (Herceptin)
Treatment of HER2+ breast carcinoma